Table 1 Baseline Characteristics and Baseline OHQ Scoresa
From: Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension
Variable | Pooled Studies | |
|---|---|---|
Droxidopa | Placebo | |
Baseline characteristics | ||
N | 225 | 235 |
Male sex, n (%) | 132 (58.7) | 142 (60.4) |
White race, n (%) | 220 (97.8) | 221 (94.0) |
Mean ± SD age, y | 65.0 ± 14.7 | 65.4 ± 14.6 |
Primary clinical diagnosis, n (%) | ||
Parkinson disease | 150 (66.7) | 157 (66.8) |
Pure autonomic failure | 34 (15.1) | 38 (16.2) |
Multiple system atrophy | 31 (13.8) | 25 (10.6) |
Nondiabetic autonomic neuropathy | 4 (1.8) | 9 (3.8) |
Dopamine ß-hydroxylase deficiency | 0 | 1 (0.4) |
Other | 6 (2.7) | 5 (2.1) |
Baseline OHQ scores | ||
Mean ± SD OHQ composite score (n) | 5.9 ± 1.7 (224) | 5.8 ± 1.9 (232) |
Mean ± SD OHSA scores, n | 225 | 235 |
Item 1 | 6.0 ± 2.2 | 5.8 ± 2.4 |
Item 2 | 4.3 ± 2.9 | 3.7 ± 2.9 |
Item 3 | 5.8 ± 2.5 | 5.6 ± 2.7 |
Item 4 | 5.9 ± 2.4 | 5.9 ± 2.6 |
Item 5 | 4.6 ± 2.7 | 4.7 ± 2.8 |
Item 6 | 4.0 ± 3.2 | 4.4 ± 3.3 |
Composite score | 5.6 ± 1.7 | 5.5 ± 1.8 |
Mean ± SD OHDAS scores (n) | ||
Item 1 | 5.1 ± 2.8 (223) | 5.3 ± 2.8 (230) |
Item 2 | 7.0 ± 2.4 (214) | 6.9 ± 2.8 (229) |
Item 3 | 4.9 ± 2.9 (223) | 4.7 ± 2.9 (228) |
Item 4 | 6.7 ± 2.8 (211) | 6.6 ± 3.0 (223) |
Composite score | 6.2 ± 2.0 (224) | 6.1 ± 2.3 (231) |